MedPath

A study to check the safety & benefit of medicine Trivoglitor in patients with type 2 diabetes mellitus.

Not Applicable
Conditions
Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
Registration Number
CTRI/2023/06/053828
Lead Sponsor
Torrent Pharmaceuticals Ltd,
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Uncontrolled T2DM >= 7% HbA1c, FBG > 100 mg/dL & PPBG >= 200 mg/dL

2) Patients of either sex, above 18 years of age with T2DM and who had received treatment with FDC of glimepiride, metformin sustained release (SR) and voglibose of any strength

Exclusion Criteria

1) Patients who had incomplete data or any condition that according to the discretion of the investigator indicated that the patient is not suitable for the study were excluded. Duration

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath